DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20-364/S-046 **SUPPLEMENT APPROVAL**

Novartis Pharmaceuticals Corporation
Attention: Nancy A. Price
Executive Director, Drug Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Ms. Price:

Please refer to your supplemental new drug application dated May 21, 2009, received May 21, 2009, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lotrel (amlodipine besylate/benazepril hydrochloride) 2.5/10 mg, 5/10 mg, 5/20 mg, 5/40 mg, 10/20 mg, and 10/40 mg Capsules.

This "Changes Being Effected" supplemental new drug application provides for changes to the CONTRAINDICATIONS and PRECAUTIONS sections of the label. The following changes have been made:

1. In **CONTRAINDICATIONS**, the first paragraph has been changed from:

   Lotrel is contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine.

   To:

   Lotrel is contraindicated in patients with a history of angioedema, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, or to amlodipine.

2. In **PRECAUTIONS/Drug Interactions**, the following has been added to the list of interactions:

   Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.

3. The revision date and version number have been updated.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed upon labeling text.

CONTENT OF LABELING

Within 14 days from the date of this letter, please amend all pending supplemental applications for this NDA, including pending "Changes Being Effected" (CBE) supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format that includes the changes approved in this supplemental application.

We also note that your May 21, 2009, submission includes final printed labeling (FPL) for your patient package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

If you have any questions, please call:

Lori Anne Wachter, RN, BSN
Regulatory Project Manager
(301) 796-3975

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm. D.
Deputy Director for Safety
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure
Agreed-upon labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-20364	SUPPL-46	NOVARTIS PHARMACEUTICALS CORP	LOTREL (AMLODIPIDINE/BENAZEPRIL)CAPSULES

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
10/28/2009